Antipsychotic agents in the treatment of bipolar mania

Bipolar Disorders

Volumn 11, Issue SUPPL. 2, 2009, Pages 45-54

  Tohen, Mauricio ^a   Vieta, Eduard ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Acute mania; Antipsychotics; Atypical antipsychotics; Bipolar mania; Lithium; Typical antipsychotics

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; LITHIUM SALT; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PIMOZIDE; PLACEBO; QUETIAPINE; RISPERIDONE; VALPROATE SEMISODIUM; VALPROIC ACID; ZIPRASIDONE;

ADD ON THERAPY; ADJUVANT THERAPY; AGITATION; AKATHISIA; APPETITE; BIPOLAR MANIA; CLINICAL TRIAL; DEPRESSION; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSTONIA; EDEMA; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; FEVER; HUMAN; HYPERPROLACTINEMIA; HYPOTENSION; INFECTION; MANIA; MEDICAL RECORD REVIEW; MONOTHERAPY; MUSCLE RIGIDITY; PRIORITY JOURNAL; REMISSION; REVIEW; RHINITIS; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; SPEECH DISORDER; TARDIVE DYSKINESIA; TONGUE EDEMA; TREMOR; WEIGHT GAIN; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; HUMANS;

EID: 66649123127     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2009.00710.x     Document Type: Review

References (88)

1. Baldessarini RJ, Tondo L, Suppes T et al. Pharmacological treatment of bipolar disorder across the life cycle. In: Shulman KI, Tohen M, Kutcher SP eds. Mood Disorders Across the Life Span. New York: John Wiley & Sons, 1996: 299-338.
2. Delay J, Deniker P, Harl J. Utilization therapeutique psychiatrique d'une phenothiazine d'action cetrale elective (4560RP). Ann Med Psychol 1952; 110: 112-117.
3. Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G. One hundred years of schizophrenia: A meta-analysis of the outcome literature. Am J Psychiatry 1994; 151: 1409-1416.
4. Kendell RE, Pichot P, Van Cranach M. Diagnostic criteria of English, French, German psychiatrists. Psychol Med 1974; 4: 187-195.
5. Tohen M, Zarate CA Jr. Antipsychotic agents and bipolar disorder. J Clin Psychiatry 1998; 59 (Suppl. 1): 38-48.
6. Janicak PG, Newman RH, Davis JM. Advances in the treatment of mania and related disorders: A reappraisal. Psychiatr Ann 1992; 22: 92-103.
7. Prien RF, Point P, Caffey E et al. Comparison of lithium carbonate and chlorpromazine in the treatment of mania. Arch Gen Psychiatry 1972; 26: 146-153.
8. Hirschfeld RM, Clayton PJ, Cohen I et al. Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry 1994; 151 (Suppl. 1): 1-36.
9. Tohen M, Zhang F, Taylor CC et al. A meta-analysis of the use of typical antipsychotic agents in bipolar disorder. J Affect Disord 2001; 65: 85-93.
10. Garfinkle PE, Stancer HG, Persad E. A comparison of haloperidol, lithium carbonate and their combination in the treatment of mania. J Affect Disord 1980; 2: 279-288.
11. Cookson J, Silverstone T, Wells B. Double-blind comparative clinical trial of pimozide and chlorpromazine in mania. Acta Psychiatr Scand 1981; 64: 381-397.
12. Shopsin B, Gershon S, Thompson H, Collins P. Psychoactive drugs in mania: A controlled comparison of lithium carbonate, chlorpromazine, and haloperidol. Arch Gen Psychiatry 1975; 32: 34-42.
13. Janicak PG, Bresnahan DB, Sharma RP, Davis JM, Comaty JE, Malinick C. A comparison of thiothixene with chlorpromazine in the treatment of mania. J Clin Psychopharmacol 1988; 8: 33-37.
14. Zarate CA Jr, Tohen M. Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. Am J Psychiatry 2004; 161: 169-171.
15. Kein DF. Importance of psychiatric diagnosis in prediction of clinical drug effects. Arch Gen Psychiatry 1967; 16: 118-126.
16. Smulevich AB, Khanna S, Eerdekens M, Karcher K, Kramer M, Grossman F. Acute and continuation risperidone monotherapy in bipolar mania: A 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol 2005; 15: 75-84.
17. McIntyre RS, Brecher M, Paulsson B, Huizar K, Mullen J. Quetiapine or haloperidol as monotherapy for bipolar mania -a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol 2005; 15: 573-585.
18. Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: A double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 2002; 159: 1146-1154.
19. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry 2003; 60: 1218-1226.
20. Müller-Oerlinghausen B, Retzow A, Henn FA, Giedke H, Walden J. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: A prospective, randomized, double-blind, placebo-controlled, multicenter study. European Valproate Mania Study Group. J Clin Psychopharmacol 2000; 20: 195-203.
21. Vieta E, Bourin M, Sanchez R et al. Effectiveness of aripiprazole vs. haloperidol in acute bipolar mania: Double-blind, randomised, comparative 12-week trial. Br J Psychiatry 2005; 187: 235-242.
22. Vieta E, T'joen C, McQuade RD et al. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium: A placebo-controlled study. Am J Psychiatry 2008; 165: 1316-1325.
23. Barbini B, Scherillo P, Benedetti F, Crespi G, Colombo C, Smeraldi E. Response to clozapine in acute mania is more rapid than that of chlorpromazine. Int Clin Psychopharmacol 1997; 12: 109-112.
24. Baldessarini RJ, Cohen BM, Teicher MH. Significance of Neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988; 45: 79-91.
25. Rifkin A, Doddi S, Karajgi B, Borenstein M, Munne R. Dosage of haloperidol for mania. Br J Psychiatry 1994; 165: 113-116.
26. Nasarallah HA, Churchill CM, Hamdan-Allan GA. Higher frequency of neuroleptic-induced dystonia in mania than in schizophrenia. Am J Psychiatry 1988; 145: 1455-1456.
27. Kane JM, Smith JM. Tardive Dyskinesia: Prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 1982; 39: 473-481.
28. Kane JM. The role of neuroleptics in manic-depressive illness. J Clin Psychiatry 1988; 49 (Suppl. 11): 12-13.
29. Cavazzoni PA, Berg PH, Kryzhanovskaya LA et al. Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials. J Clin Psychiatry 2006; 67: 107-113.
30. Zarate CA Jr, Tohen M, Baldessarini RJ. Clozapine in severe mood disorders. J Clin Psychiatry 1995; 56: 411-417.
31. Zarate CA Jr, Tohen M, Banov MD, Weiss MK, Cole JO. Is clozapine a mood stabilizer? J Clin Psychiatry 1995; 56: 108-112.
32. Banov MD, Zarate CA Jr, Tohen M et al. Clozapine therapy in refractory affective disorders; polarity predicts response in long-term follow-up. J Clin Psychiatry 1994; 55: 295-300.
33. McElroy SL, Dessain EC, Pope HG Jr et al. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J Clin Psychiatry 1991; 52: 411-414.
34. Suppes T, McElroy S, Gilbert J, Dessain EC, Cole JO. Clozapine in the treatment of dysphoric mania. Biol Psychiatry 1992; 32: 270-280.
35. Calabrese JR, Kimmel SE, Woyshville MJ et al. Clozapine for treatment-refractory mania. Am J Psychiatry 1996; 153: 759-764.
36. Green AI, Tohen M, Patel JK et al. Clozapine in the treatment of refractory psychotic mania. Am J Psychiatry 2000; 157: 982-986.
37. Keck PE Jr, Marcus R, Tourkodimitris S et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003; 160: 1651-1658.
38. Lyseng-Williamson KA, Perry CM. Aripiprazole: In acute mania associated with bipolar I disorder. CNS Drugs 2004; 18: 367-376.
39. Sachs G, Sanchez R, Marcus R et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: A 3-week placebo-controlled study. J Psychopharmacol 2006; 20: 536-546.
40. Tohen M, Sanger TM, McElroy SL et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry 1999; 156: 702-709.
41. Tohen M, Jacobs TG, Grundy SL et al. Efficacy of olanzapine in acute bipolar mania: A double-blind, placebo-controlled study. The Olanzapine HGGW Study Group. Arch Gen Psychiatry 2000; 57: 841-849.
42. Tohen M, Baker RW, Altshuler LL et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 2002; 159: 1011-1017.
43. Tohen M, Ketter TA, Zarate CA Jr et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: A 47-week study. Am J Psychiatry 2003; 160: 1263-1271.
44. Zajecka JM, Weisler R, Sachs G, Swann AC, Wozniak P, Sommerville KW. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2002; 63: 1148-1155.
45. Tohen M, Vieta E, Goodwin G et al. Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: A randomized, 12-week, double-blind study. J Clin Psychiatry 2008; 69: 1776-1789.
46. Niufan G, Tohen M, Quiqing A et al. Olanzapine versus lithium in the acute treatment of bipolar mania: A double-blind, randomized, controlled trial. J Affect Disord 2008; 105: 101-118.
47. Tohen M, Chengappa KN, Suppes T et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002; 59: 62-69.
48. Tohen M, Bowden CL, Smulevich AB et al. Olanzapine plus carbamazepine vs. carbamazepine alone in treating manic episodes. Br J Psychiatry 2008; 192: 135-143.
49. Vieta E, Mullen J, Brecher M, Paulsson B, Jones M. Quetiapine monotherapy for mania associated with bipolar disorder: Combined analysis of two international, double-blind, randomised, placebo-controlled studies. Curr Med Res Opin 2005; 21: 923-934.
50. Sachs G, Chengappa KN, Suppes T et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: A randomized, double-blind, placebo-controlled study. Bipolar Disord 2004; 6: 213-223.
51. Yatham LN, Vieta E, Young AH, Möller HJ, Paulsson B, VageröM. A double blind, randomized, placebo-controlled trial of quetiapine as an add-on therapy to lithium or divalproex for the treatment of bipolar mania. Int Clin Psychopharmacol 2007; 22: 212-220.
52. Bowden CL, Grunze H, Mullen J et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005; 66: 111-121.
53. Tohen M, Zarate C, Centorrino F, Hegarty JD, Froeshl M, Zarate SB. Risperidone in the treatment of mania. J Clin Psychiatry 1996; 57: 249-253.
54. Hirschfeld RM, Keck PE Jr, Kramer M et al. Rapid antimanic effect of risperidone monotherapy: A 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry 2004; 161: 1057-1065.
55. Khanna S, Vieta E, Lyons B, Grossman F, Eerdekens M, Kramer M. Risperidone in the treatment of acute mania: Double-blind, placebo-controlled study. Br J Psychiatry 2005; 187: 229-234.
56. Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br J Psychiatry 2003; 182: 141-147.
57. Keck PE Jr, Versiani M, Potkin S et al. Ziprasidone in the treatment of acute bipolar mania: A three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003; 160: 741-748.
58. Potkin SG, Keck PE Jr, Segal S, Ice K, English P. Ziprasidone in acute bipolar mania: A 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol 2005; 25: 301-310.
59. Vieta E, Ramey T, Keller D, English P, Loebel A, Miceli J. Ziprasidone in the treatment of acute mania: A 12- week, placebo-controlled, haloperidol-referenced study. J Psychopharmcol 2008 Dec 12 [Epub ahead of print].
60. Weisler R, Dunn J, English P. Ziprasidone in adjunctive treatment of acute bipolar mania: Randomized, double-blind, placebo-controlled trial. 16th European College of Neuropsychopharmacology Congress, Prague, Czech Republic, 20-24 September. 2003.
61. Vieta E, Berwaerts J, Nuamah I et al. Randomized, placebo-active controlled study of paliperidone extended release for acute manic and mixed episodes in bipolar I disorder. Eur Neuropsychopharmacol 2008; 18 (Suppl. 4): S369.
62. Thomas P, Vieta E, for the SOLMANIA study group. Amisulpride plus valproate vs haloperidol plus valproate in the treatment of acute mania of bipolar I patients: A multicenter, open-label, randomized, comparative trial. Neuropsychiatr Dis Treat 2008; 4: 675-686.
63. Amann B, Sterr A, Mergl R et al. Zotepine loading in acute and severely manic patients: A pilot study. Bipolar Disord 2005; 7: 471-476.
64. McIntyre R, Panagides J, Alphs L et al. Efficacy and tolerability of asenapine and olanzapine in acute mania: A double-blind extension study (ARES 7501006). Presented at the 20th ECNP Meeting, Vienna, 13-17 October. 2007.
65. Perlis RH, Baker RW, Zarate CA Jr et al. Olanzapine vs. risperidone in the treatment of manic or mixed states in bipolar I disorder: A randomized, double-blind trial. J Clin Psychiatry 2006; 67: 1747-1753.
66. Smith LA, Cornelius V, Warnock A, Tacchi MJ, Taylor D. Pharmacological interventions for acute bipolar mania: A systematic review of randomized placebo-controlled trials. Bipolar Disord 2007; 9: 551-560.
67. Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: A systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry 2007; 64: 442-455.
68. Pope HG Jr, McElroy SL, Keck PE Jr, Hudson JI. Valproate in the treatment of acute mania. A placebo controlled study. Arch Gen Psychiatry 1991; 48: 62-68.
69. Torrent C, Amann B, Sanchez-Moreno J et al. Weight gain in bipolar disorder: Pharmacological treatment as a contributing factor. Acta Psychiatr Scand 2008; 118: 4-18.
70. Ng F, Mammen OK, Wilting I et al. The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. Bipolar Disord 2009; In press.
71. Tohen M. Mania. In: Sederer LI, Rothschild AJ eds. Acute Care Psychiatry: Diagnosis and Treatment. Baltimore, MD: Williams & Wilkins, 1997: 141-165.
72. Van Riel WG, Vieta E, Martínez-Arán A et al. Chronic mania revisited: Factors associated with treatment non-response during prospective follow-up of a large European cohort (EMBLEM). World J Biol Psychiatry 2008; 9: 313-320.
73. Tohen M, Zarate CA, Hennen J et al. The McLean Harvard first-episode mania study; prediction of recovery and first recurrence. Am J Psychiatry 2003; 160: 2099-2107.
74. Vieta E, Colom F. Psychological interventions in bipolar disorder: From wishful thinking to an evidence-based approach. Acta Psychiatr Scand Suppl 2004; 422: 34-38.
75. Scott J, Colom F, Vieta E. A meta-analysis of relapse rates with adjunctive psychological therapies compared to usual psychiatric treatment for bipolar disorders. Int J Neuropsychopharmacol 2007; 10: 123-129.
76. Brecher M, Huizar K. Quetiapine vs. placebo for acute mania associated with bipolar disorder (STAMP1). Bipolar Disord 2003; 5 (Suppl. 1): 35-36.
77. Paulsson B, Huizar K. Quetiapine monotherapy vs. placebo for acute bipolar mania (STAMP2). Bipolar Disord 2003; 5 (Suppl. 1): 74.
78. Vieta E, Khanna S, Lyons B, Grossman F, van Kammen D, Kramer M. Risperidone in the treatment of manic or mixed episodes of bipolar disorder. Poster presented at the American College of Neuropsychopharmacology, 41st Annual Meeting, Puerto Rico, December 8-12, 2002.
79. Bowden CL, Brugger AM, Swann AC et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994; 271: 918-924.
80. Weisler R, Kalali A, Ketter T, SPD417 Study Group. A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry 2004; 65: 478-484.
81. Weisler R, Keck P, Swann A et al. Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: A multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2005; 66: 323-330.
82. DelBello MP, Kowatch RA, Adler CM et al. A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry 2006; 45: 305-313.
83. Tohen M, Vieta E, Calabres J et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60: 1079-1088.
84. Biederman J, Mick E, Hammerness P et al. Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children. Biol Psychiatry 2005; 58: 589-594.
85. Brown EB, McElroy SL, Keck PE Jr et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 2006; 67: 1025-1033.
86. Guille C, Sachs GS, Ghaemi SN. A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2000; 61: 638-642.
87. Vieta E, Ros S, Goikolea JM et al. An open-label study of amisulpride in the treatment of mania. J Clin Psychiatry 2005; 66: 575-578.
88. Tohen M, Greil W, Calabrese J et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: A 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005; 162: 1281-1290.